Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this prospective randomized study,all patients in control group will receive blank placebo ,all patients in test group will receive tongxinluo.All patients will be followed up for one year.
The primary endpoint is Platelet Reaction Unit( by VerifyNow) at 30 days.The secondary endpoints include inflammation marker (hsCRP、CD62P-CD41),TT,FIB and PT at 30 days,and MI、Ischemic Stroke, target vessel revascularization and all-cause mortality 、bleeding events at 1 year.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
134
Tongxinluo,3 capsules/time 3times/day for 1 year
3 capsules/time，3times/day for 1 year
ShenZhou Hopital Of ShenYang Medical College
ShengYang, Liaoning, China
The 463th Hospital Of PLA
Shenyang, Liaoning, China
Northern Hospital
Shenyang, Liaoning, China
Platelet reaction unit(PRU) measured by verifyNow
to measure the rate of HPR(PRU ≤ 235)
Time frame: 1 month
Inflammation Marker (hsCRP、CD62P-CD41)
Time frame: 1 month
Plasma fibrinogen concentration
Time frame: 1 month
Thrombin time
Time frame: 1 month
Prothrombin time
Time frame: 1 month
major adverse cardiovascular events
Including MI,Stroke,target vessel revascularization,and all-cause mortality
Time frame: 1 year
bleeding event
Time frame: 1 year
Adverse drug reaction and withdrawal rate
Time frame: 1 month ，1 year
Angina recurrence
Time frame: 1 year
Traditional Chinese medicine angina symptoms scores
Time frame: 1 year
Intra-stent thrombosis
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.